DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02084654

CompletedPhase 1

Exenatide and Weight Loss for Diabetes Prevention

Randomized Trial Investigating Exenatide for Diabetes Prevention in Obese, Insulin-Resistant Individuals With Prediabetes

Asset

Exenatide

GLP-1 agonist

Listed sites

0

Recruiting sites

—

Enrollment

66

actual

Study population

Obesity / overweight, Prediabetes / glucose intolerance

Key I/E criteria

•BMI 27-37•Healthy volunteers

Primary endpoint

•First-phase insulin response

Identifiers

Registered as

NCT IDNCT02084654
Org study ID9946

Timeline

Milestones

Study first posted2014-03-12estimated
Last update posted2016-11-04estimated
Study start2007-11 (month precision)
Primary completion2012-10actual (month precision)
Study completion2013-02actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Obesity / overweightPrediabetes / glucose intolerance

Eligibility

Who can enroll

Minimum age30 Years
Maximum age70 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Healthy Men and women, BMI 27-37kgm2, Fasting plasma glucose = or > 100 mg/dL and = or < 99 125m g/dl or a 2 hour post OGTT = > 140 mg/dl or = or < 199 mg/dl

Exclusion criteria

•Diabetes, Active cardiac, kidney, liver, pulmonary, or other major organ diseases are cause for exclusion. Other exclusionary criteria include: use of corticosteroids, diet medications, antipsychotic medications, history of eating disorder, history of bariatric surgery, active malignancy, recent weight change of more than 2%, inability to attend follow-up visits, excessive alcohol use, investigator's discretion that it is not in patient's best interest

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

3 endpoints
Primary/protocol endpoint/low confidence

First-phase insulin response

Time frame:7 months

change from baseline, improvement

Secondary/protocol endpoint

glucose lowering effect

Time frame:8 months

Postprandial glucose

change from baseline, improvement

Other/protocol endpoint

insulin-mediated glucose uptake (insulin sensitivity)

Time frame:8 months

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.